EF Hutton Acquisition Co. I Upgrades GeoVax Labs (NASDAQ:GOVX) to Strong-Buy

GeoVax Labs (NASDAQ:GOVX) was upgraded by EF Hutton Acquisition Co. I to a “strong-buy” rating in a research report issued on Tuesday, Zacks.com reports.

A number of other analysts have also recently commented on the company. Roth Mkm assumed coverage on GeoVax Labs in a research report on Tuesday, July 16th. They set a “buy” rating and a $20.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research report on Tuesday, July 2nd. Finally, Roth Capital upgraded GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 16th.

GeoVax Labs Trading Down 2.3 %

GeoVax Labs stock opened at $2.58 on Tuesday. GeoVax Labs has a one year low of $1.09 and a one year high of $9.75. The stock has a fifty day moving average of $2.23 and a 200 day moving average of $2.42.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($2.47) EPS for the quarter. As a group, sell-side analysts forecast that GeoVax Labs will post -7.41 earnings per share for the current fiscal year.

Institutional Trading of GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Armistice Capital LLC purchased a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned approximately 91.38% of GeoVax Labs as of its most recent SEC filing. 6.09% of the stock is owned by hedge funds and other institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.